Kháng Aspirin: Kỹ Thuật Đánh Giá Lâm Sàng và Di truyền Học Phân Tử

Insul’t: diagnostika, lechenie, profilaktika (Stroke: Diagnostics, Treatment, and Prevention), Suslina, Z.A. and Piradov, M.A., Eds., Moscow, 2008. Ionova, V.G., Suslina, Z.A., and Demina, E.G., RF Patent 2188419, 2002 Orlov, S.V., Domashenko, M.A., Kostyreva, M.V., and Tanashyan, M.M., Hemorheology and hemostasis in patients suffering from ischemic cerebral stroke and metabolic syndrome, Klin. Med., 2007, vol. 1, pp. 40–44. Piradov, M.A., Antiaggregant therapy in the prevention of recurrent ischemic strokes, Russ. Med. Zh., 2003, vol. 11, no. 12, pp. 696–698. Suslina, Z.A., Tanashyan, M.M., and Ionova, V.G., Ishemicheskii insul’t: krov’, sosudistaya stenka, antitromboticheskaya terapiya (Ischemic Stroke: Blood, Vascular Wall, and Antithrombotic Therapy), Moscow: Meditsina, 2005. Suslina, Z.A., Ischemic disorders of cerebral circulation and the system of prostanoids: clinical and biochemical analysis, Doctoral (Med.) Dissertation, Moscow, 1990. Suslina, Z.A. and Vysotskaya, V.G., Antiaggregatory and clinical effects of small doses of aspirin for the treatment of patients with cerebrovascular pathology associated with arterial hypertension, Klin. Med., 1983, no. 9, p. 51. Suslina, Z.A., Tanashyan, M.M., Ionova, V.G., et al., Use of cavinton for the treatment of patients with ischemic impairment of cerebral circulation: new aspects of action, Lech. Nervn. Bolezn., 2002, vol. 3, no. 3, pp. 19–24. Suslina, Z.A., Tanashyan, M.M., and Domashenko, M.A., Antitromboticheskaya terapiya ishemicheskikh narushenii mozgovogo krovoobrashcheniya s pozitsii dokazatel’noi meditsiny (Antithrombotic Therapy of Ischemic Disorders of Cerebral Circulation from the Standpoint of Evidence-Based Medicine), Moscow: Med. Inf. Agentstvo, 2009. Suslina, Z.A., Tanashyan, M.M., and Domashenko, M.A., The problem of resistance to antiplatelet agents in patients with cerebrovascular diseases, Vestn. Ross. Akad. Med. Nauk, 2011, no. 7, pp. 3–8. Tanashyan, M.M., Ionova, V.G., Orlov, S.V., et al., Chronic cerebrovascular diseases, metabolic syndrome, and the state of hemorheology and hemostasis systems, Ter. Arkh., 2010, no. 10, pp. 19–24. Tanashyan, M.M., Orlov, S.V., Domashenko, M.A., and Ionova, V.G., Metabolic syndrome and ischemic stroke, Ann. Klin. Eksp. Nevrol., 2007, vol. 1, no. 3, pp. 5–11. Tanashyan, M.M., Khamidova, Z.M., Ionova, V.G., et al., RF Patent 2012106483/15 (009859). Khamidova, Z.M., Cerebrovascular pathology: hemorheological and genetic factors of progression, Cand. Sci. (Med.) Dissertation, Moscow, 2013. Andrioli, G. et al., Defective platelet response to arachidonic acid and thromboxane A2 in subjects with Pl (A2) polymorphism of beta(3)subunit (glycoprotein IlIa), Br. J. Haematol., 2000, vol. 110, pp. 911–918. Angiolillo, D.J., Antiplatelet therapy in type 2 diabetes mellitus, Curr. Opin. Endocrinol. Diabetes Obes., 2007, vol. 14, pp. 124–131. Bousser, M.G., Amarenco, P., Chamorro, A., et al., PERFORM Study Investigators Terutroban versus aspirin in patients with cerebral ischemic events (PERFORM): a randomised, double-blind, parallel-group trial, Lancet, 2011, vol. 377, no. 9782, pp. 2013–2022. Calkin, A.C., Drew, B.G., Ono, A., et al., Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux, Circulation, 2009, vol. 120, no. 21, pp. 2095–2104. Craven, L.L., Prevention of coronary and cerebral thrombosis, Miss. Val. Med. J., 1956, vol. 78, no. 5, pp. 213–215. Davi, G. and Patrono, C., Platelet activation and atherothrombosis, N. Engl. J. Med., 2007, vol. 357, no. 24, pp. 2482–2494. Eikelboom, J.W. et al., Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction: stroke, or cardiovascular death in patients at high risk for cardiovascular events, Circulation, 2002, vol. 105, no. 14, pp. 1650–1655. Eikelboom, J.W. et al., Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk, Circulation, 2008, vol. 118, no. 17, pp. 1705–1712. European Stroke Organization (ESO) Executive Committee, ESO Writing Committee, Guidelines for management of ischemic stroke and transient ischemic attack 2008, Cerebrovasc. Dis., 2008, vol. 25, no. 5, pp. 457–507. Fan, L., Cao, J., Liu, L., et al., Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease, Gerontology, 2013, vol. 59, pp. 122–131. Friend, M., Vucenik, I., and Miller, M., Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia, Br. Med. J., 2003, vol. 326, no. 7380, pp. 82–83. Gorelick, P.B., North American perspective of antiplatelet agents, in Advances in Neurology: Ischemic Stroke, Barnett, H.J.M., Bogousslavsky, J., and Meldrum, H., Eds., Philadelphia, Pa: Williams and Wilkins, 2003, vol. 92, pp. 281–291. Grotemeyer, K., et al., Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients, Thromb. Res., 1993, vol. 71, pp. 397–403. Guyatt, G.H., Akl, E.A., Crowther, M., et al., Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients, Chest, 2012, vol. 141, no. 2, pp. 7S–47S. Halushka, M. et al., Genetic variation in cyclooxygenase 1: effects on response to aspirin, Clin. Pharmacol. Ther., 2003, vol. 73, pp. 122–130. Hankey, G.J. and Eikelboom, J.W., Aspirin resistance, Lancet, 2006, vol. 367, no. 9510, pp. 606–617. Jauch, E.C., Saver, J.L., Adams, H.P., et al., Guidelines for the early management of patients with acute ischemic stroke. A guideline for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 2013, vol. 44, no. 3, pp. 870–947. Karepov, V., Tolpina, G., Kuliczkowski, W., and Serebruany, V., Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke, Cerebrovasc. Dis., 2008, vol. 26, no. 3, pp. 272–276. Krasopoulos, G. et al., Aspirin resistance and risk of cardiovascular morbidity: systematic review and metaanalysis, Br. Med. J., 2008, vol. 336, no. 7637, pp. 195–198. Lordkipanidze, M., Diodati, J.G., Palisaitis, D.A., et al., Genetic determinants of response to aspirin: appraisal of 4 candidate genes, Thromb. Res., 2011, vol. 128, pp. 47–53. Lordkipanidzé, M., Advances in monitoring of aspirin therapy, Platelets, 2012, vol. 23, no. 7, pp. 526–536. Macchi, L., Sorel, N., and Christiaens, L., Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance, Curr. Pharm. Des., 2006, vol. 12, no. 2, pp. 251–258. Meschia, J.F., Bushnell, C., Boden-Albala, B., et al., Guidelines for the primary prevention of stroke. A statement for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 2014, vol. 45, no. 12, pp. 3754–3832. Michelson, A. et al., Resistance to antiplatelet drugs, Eur. Heart. J., 2006, vol. 8, suppl. G, pp. 53–58. Michelson, A.D. et al., Aspirin resistance: position paper of the working group on aspirin resistance, J. Thromb. Haemostasis, 2005, vol. 3, pp. 1309–1311. Patrono, C., García Rodríguez, L.A., Landolfi, R., and Baigent, C., Low-dose aspirin for the prevention of atherothrombosis, N. Engl. J. Med., 2005, vol. 353, no. 22, pp. 2373–2383. Paul, R., Banerjee, A.K., Guha, S., et al., Study of platelet aggregation in acute coronary syndrome with special reference to metabolic syndrome, Int. J. Appl. Basic Med. Res., 2013, vol. 3, no. 2, pp. 117–121. Vane, J.R., Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nat. New Biol., 1971, vol. 231, no. 25, pp. 232–235. Weisman, S.M. and Rabe, C.S., Aspirin: new tricks for an old drug, Primary Care Rep., 1998, vol. 4, pp. 239–246. Weng, Z., Li, X., Li, Y., et al., The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis, PLoS One, 2013, vol. 8, p. e78093.